# A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

Study · id `cardio:ct-nct05624853` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05624853](<https://clinicaltrials.gov/study/NCT05624853>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05624853

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT05624853. Randomized; no masking; primary purpose treatment. Start 2020-05-12 (actual); primary completion 2022-12-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT05624853, source copy `cardio:ctgov-nct05624853-2023-10-23`, retrieved 2026-10-26)
- Started: 2020-05-12 (actual) (ClinicalTrials.gov record NCT05624853, source copy `cardio:ctgov-nct05624853-2023-10-23`, retrieved 2026-10-26)
- Primary completion: 2022-12-20 (actual) (ClinicalTrials.gov record NCT05624853, source copy `cardio:ctgov-nct05624853-2023-10-23`, retrieved 2026-10-26)
- Completion: 2022-12-20 (actual) (ClinicalTrials.gov record NCT05624853, source copy `cardio:ctgov-nct05624853-2023-10-23`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05624853, source copy `cardio:ctgov-nct05624853-2023-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05624853-2023-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
- Condition: Neuropathic Pain
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): pregabalin sustained release tablet
- Intervention (Drug): pregabalin immediate release capsule
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A phase 4 randomized active-controlled clinical study to compare the efficacy and safety of sustained-release pregabalin with immediate-release pregabalin in type 2 diabetic patients with peripheral neuropathic pain (`cardio:pubmed-39018898`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2465a481092b6cfb0cc5a4db8bac210752bbb0edee99821747fd88d998c98bde
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
